- Home
- VRCA
as 11-11-2025 2:34pm EST
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WEST CHESTER |
| Market Cap: | 32.7M | IPO Year: | 2018 |
| Target Price: | N/A | AVG Volume (30 days): | 247.5K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.28 - $13.60 | Next Earning Date: | 11-06-2025 |
| Revenue: | $14,704,000 | Revenue Growth: | 5.72% |
| Revenue Growth (this year): | 332.45% | Revenue Growth (next year): | 12.85% |
Latest Verrica Pharmaceuticals Inc. News
VRCA Breaking Stock News: Dive into VRCA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
MT Newswires
23 days ago
Verrica Pharmaceuticals Cleared to File for EU Approval of Molluscum Treatment
GlobeNewswire
23 days ago
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
Simply Wall St.
5 months ago
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA): Are Analysts Optimistic?
GlobeNewswire
5 months ago
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
Thomson Reuters StreetEvents
6 months ago
Q1 2025 Verrica Pharmaceuticals Inc Earnings Call
GuruFocus.com
6 months ago
Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlights: Strong YCANTH Demand and ...
Zacks
6 months ago
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Compare VRCA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRCA Verrica Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.